

Overview

Keywords & Expertise

Objectives

Deliverables

COST Policy Plans

Network of Proposers

Action Parties

MC Observers

MC Participants


Leadership Positions

MC Decisions

Networking Tools

« COST Actions

Overview

 COST Action CA19114, [Network for Optimized Astatine labeled Radiopharmaceuticals](#)

Action status:	Running				
Start Date:	22 October 2020	End Date:	21 October 2024	Former end date:	
CSO Approval Date:	24 March 2020	Entry Into Force:	28 April 2020	1st MC meeting:	22 October 2020
The action will end on Monday, October 21, 2024					

Action Chair: [Dr Jean-François GESTIN](#)
Science Officer: [Dr Inga Dadeshidze](#)
Administrative Officer: [Ms Jeannette Nchung Oru](#)

Description

Cancer is a major health concerns for European citizens. Thus, the main research aim of this **Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR)** COST Action is to successfully demonstrate that one of the most promising radionuclides for Targeted Alpha Therapy (TAT), namely astatine-211, can become the European standard for treatment of certain cancerous pathologies. To this end, an efficient networking is essential among all European stakeholders interested in promoting astatine-211 for medical applications.

NOAR COST Action brings together European and international excellence labs, astatine-211 production centers, hospitals, industry and patient associations from more than 20 countries, thus covering the whole value chain of innovation: production, chemistry, radiochemistry, biology, preclinical and clinical research and delivery of radiopharmaceuticals to patients.

A **European web portal** will be created containing information for patients, practitioners, researchers, Industry and as a contact point for National and European patient associations.

The idea is to gather forces at the European level in order to implement actions to leverage hurdles to the development of this powerful radionuclide and to identify pathologies in which it will be particularly relevant.

A special emphasis will be given to train a new generation of young researchers and PhD students, promoting interdisciplinary competences through international and inter-sectoral mobility.

The long-term goal of this project is to make Astatine-211 technology available to all European citizens.

Public links

 [Description](#)

 [Parties](#)

 [Management committee](#)

Available Files

[AFS](#) 

[MoU](#) 